AstraZeneca (LON:AZN)‘s stock had its “hold” rating reissued by investment analysts at Liberum Capital in a research note issued to investors on Monday. They presently have a GBX 5,000 ($69.08) price objective on the biopharmaceutical company’s stock. Liberum Capital’s price objective would suggest a potential upside of 4.48% from the company’s previous close.
Other equities research analysts also recently issued reports about the company. Shore Capital restated a “hold” rating on shares of AstraZeneca in a research report on Monday. JPMorgan Chase & Co. restated an “overweight” rating and issued a GBX 5,500 ($75.99) target price on shares of AstraZeneca in a research report on Friday, February 2nd. Goldman Sachs Group set a GBX 3,800 ($52.50) target price on AstraZeneca and gave the stock a “sell” rating in a research report on Monday, February 5th. Barclays restated a “top pick” rating and issued a GBX 6,300 ($87.04) target price on shares of AstraZeneca in a research report on Monday, February 5th. Finally, Berenberg Bank upped their target price on AstraZeneca from GBX 5,800 ($80.13) to GBX 6,000 ($82.90) and gave the stock a “buy” rating in a research report on Thursday, February 8th. Four equities research analysts have rated the stock with a sell rating, seven have given a hold rating, twelve have assigned a buy rating and one has issued a strong buy rating to the company’s stock. AstraZeneca presently has an average rating of “Hold” and an average price target of GBX 5,199.70 ($71.84).
Shares of AstraZeneca (LON:AZN) opened at GBX 4,785.50 ($66.12) on Monday. The firm has a market capitalization of $61,000.00 and a P/E ratio of 2,815.00. AstraZeneca has a 52-week low of GBX 4,260 ($58.86) and a 52-week high of GBX 5,520 ($76.26).
TRADEMARK VIOLATION NOTICE: This story was posted by Ticker Report and is the sole property of of Ticker Report. If you are accessing this story on another publication, it was copied illegally and republished in violation of U.S. & international trademark & copyright legislation. The legal version of this story can be accessed at https://www.tickerreport.com/banking-finance/3256628/liberum-capital-reaffirms-hold-rating-for-astrazeneca-azn.html.
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.